Akers Biosciences, Inc. European Distribution Agreements (1204A)
December 18 2014 - 1:00AM
UK Regulatory
TIDMAKR
RNS Number : 1204A
Akers Biosciences, Inc.
18 December 2014
Embargoed: 0700hrs 18 December 2014
Akers Biosciences, Inc.
European Distribution Agreements for PIFA Heparin PF4 Rapid
Assay Products
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the
"Company"), a leading designer and manufacturer of rapid diagnostic
screening and testing products, has entered into its first European
distribution agreements since the installment of its international
vice president in August 2014. The Company has entered into
multi-year distribution agreements for PIFA Heparin/PF4 Rapid Assay
products with Cryopep SARL, covering France, Belgium, the
Netherlands and Luxembourg; and DiaLine AG, covering Switzerland
and Lichtenstein.
The Company's PIFA Heparin/PF4 Rapid Assay and PIFA PLUSS PF4
are the only US and EU cleared rapid manual assays that quickly
determine if a patient being treated with the blood thinner heparin
may be developing a drug allergy. This clinical syndrome known as
heparin--induced thrombocytopenia ("HIT") reverses the heparin's
intended therapeutic effect and transforms it into a clotting
agent. Patients suffering HIT are at risk of developing limb- and
life-threatening complications, so the timely test result provided
by the Company's Heparin/PF4 devices is paramount to effective,
clinical decision making. Millions of patients are exposed to
heparin around the world each year and 1% to 5% of those patients
receive a HIT diagnosis. The largest at-risk populations are
patients undergoing major cardiac or orthopedic surgical
procedures.
Cryopep (headquartered in Montpellier, France) and DiaLine
(headquartered in Lausen, Switzerland) are both leaders in the
field of haemostasis, which includes coagulation disorders such as
HIT. Cryopep's managing director, Norbert Benattar, has been
involved in the sale of haemostasis related products since 1987,
including as a director of marketing and sales for Diagnostica
Stago and Horiba ABX Biogenic; while DiaLine has been distributing
haemostasis related products for over 17 years.
"Cryopep and DiaLine's respective expertise in the coagulation
business makes us confident that we have selected strong partners
to launch the PIFA Heparin/PF4 Rapid Assay products into these
European territories," said Nicolas Daurel, the Company's Vice
President Sales and Marketing for Europe, Middle East and Africa.
"I look forward to supporting their marketing strategies."
"Growing international distribution, particularly of the
Company's flagship PIFA Heparin/PF4 Rapid Assay products, is a core
component of Akers Biosciences' growth strategy," said Raymond F.
Akers, Jr. PhD, Co-founder and Executive Chairman of the Board. "I
am delighted to see the first pieces of the European network
established, adding to the already established distribution
channels in the US, China, India, Australia and the Middle
East."
ABOUT AKERS BIOSCIENCES, INC.
Akers Biosciences develops, manufactures, and supplies rapid,
point of care screening and testing products designed to bring
healthcare information both rapidly and directly to the consumer or
healthcare provider. The Company has advanced the science of
diagnostics while responding to major shifts in healthcare through
the development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical products distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found on our website at www.akersbiosciences.com. Follow us on
Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information:
Akers Biosciences, Inc.
Raymond F. Akers, Jr. PhD
Executive Chairman of the Board
Tel. +1 856 848 8698
RedChip Companies, Inc. (US Investor Relations)
Jon Cunningham
Tel. +1 407 644 4256 x107
finnCap (UK Nominated Adviser and Broker)
Geoff Nash / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel: +44 (0)20 7220 0500
Vigo Communications (UK Investor Relations)
Ben Simons / Alexandra Roper
Tel. +44 (0)20 7016 9570
Email. akers@vigocomms.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGREAFAPFLFLFEF
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Apr 2024 to May 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From May 2023 to May 2024